Publications by authors named "Sara Susca"

Claim this Profile
C
Clinical characteristics and response to biological therapies for inverse psoriasis: a real-life comparison between the therapeutic effects of anti-IL-23 and anti-IL-17 agents.
Luca Mastorino, Paolo Dapavo, Nicole Macagno, Michela Ortoncelli, Anna Verrone, Sara Susca

Int J Dermatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lichenoid drug eruption during treatment with brodalumab for psoriasis.
Nadia Sciamarrelli, Luca Mastorino, Martina Merli, Sara Susca, Sara Boskovic

Ital J Dermatol Venerol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience.
Luca Mastorino, Paolo Dapavo, Caterina Cariti, Sara Susca, Niccolò Siliquini

J Pers Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
Luca Mastorino, Paolo Dapavo, Sara Susca, Caterina Cariti, Niccolò Siliquini

J Dtsch Dermatol Ges· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-IL23 in inflammatory bowel disease patients with dermatological indication: The shared gastroenterological-dermatological clinic experience.
Davide Giuseppe Ribaldone, Andrea Palumbo, Sara Susca, Martina Merli, Paolo Dapavo

Dig Liver Dis· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors.
Luca Mastorino, Sara Susca, Caterina Cariti, Anna Verrone, Elena Stroppiana

Exp Dermatol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis.
Luca Mastorino, Caterina Cariti, Sara Susca, Niccolò Siliquini, Anna Verrone

Exp Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents.
Gabriele Roccuzzo, Luca Mastorino, Sara Susca, Caterina Cariti, Stefania G Passerini

Clin Exp Dermatol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral doxycycline in HIV-related synchronous malignant syphilis and condyloma lata.
Gianluca Avallone, Francesco Cavallo, Sara Susca, Luca Mastorino, Mattia Trunfio

Ital J Dermatol Venerol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new suture technique for flap closure in dermatologic surgery.
Michele Parietti, Sara Susca, Simone Ribero

J Am Acad Dermatol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement.
Luca Mastorino, Caterina Cariti, Sara Susca, Nadia Sciamarrelli, Silvia Borriello

Dermatol Ther· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mask-related acne flares during the COVID era.
Caterina Cariti, Francesco Cavallo, Michele Panzone, Sara Susca, Pietro Quaglino

Ital J Dermatol Venerol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risankizumab shows high efficacy and maintenance in improvement of response until week 52.
Luca Mastorino, Sara Susca, Matteo Megna, Niccolò Siliquini, Pietro Quaglino

Dermatol Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease.
Marta Vernero, Davide Giuseppe Ribaldone, Caterina Cariti, Simone Ribero, Sara Susca

J Dermatol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis